On January 10, 2026, the “West China Forum on Technology-Enabled Ostomy Development and the Academic Conference of the West China Intestinal Ostomy Nursing Specialty Alliance” was successfully held at the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU). More than 100 nursing professionals from 76 member instituti...
A clinical research project entitled “Stem Cell Therapy for Pre-Liver Failure”, led by Professor He Yingli from the Department of Infectious Diseases of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU), passed the final review and was registered with the National Stem Cell Committee on December 17, 2025. On Ja...
Immune checkpoint blockade (ICB) therapy has markedly improved outcomes for multiple cancers; however, its efficacy remains limited in prostate cancer and other “immune-cold” tumors, with clinical response rates of less than 5%. In theory, radiotherapy can enhance antitumor immunity by inducing DNA damage and activating the cGAS-STIN...
From January 7 to 8, 2026, the Land Port Division of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU) hosted its first international exchange academic event of 2026, as part of the “Distinguished Experts on Discipline Development” series. Professor Giampietro Schiavo, Fellow of the Academy of Medical Sciences ...
Recently, research from Professor Ren Juan’s team in the Department of Radiotherapy of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU), entitled “GPR4 promotes immune exclusion in colon cancer through LOXL2-mediated extracellular matrix remodeling”, was published online in the Nature Research journal Nature ...
